Type 2 diabetes is where GLP-1 receptor agonists started. Approved indications go back to 2005 (Byetta). Today the class is recommended as second-step therapy after metformin in most major guidelines, often before insulin, with strong glycemic and weight effects and an emerging cardiovascular and renal benefit profile.

What the trials show

Semaglutide (SUSTAIN program)

The SUSTAIN trials evaluated semaglutide vs placebo, vs other antidiabetic agents, and across various baseline therapies. Key results: A1c reductions of 1.4–1.8%, weight reduction of 4–6 kg, and reduced cardiovascular events in SUSTAIN-6 (the cardiovascular outcome trial). SUSTAIN-6 established that semaglutide is non-inferior and likely superior on MACE in T2D + high CV risk, leading to the 2020 expansion of Ozempic's label to include CV risk reduction.

Tirzepatide (SURPASS program)

Tirzepatide moved the bar. SURPASS-3 showed tirzepatide superior to titrated insulin degludec on both A1c and weight endpoints, with lower hypoglycemia. Across the SURPASS program, A1c reductions reached 2.0–2.5% at higher doses, with weight reductions of 8–12 kg.

Practical glycemic targets

Baseline A1c 8–9% → expect 1.5–2.0% reduction with semaglutide; 2.0–2.5% with tirzepatide at higher doses.
Baseline A1c 7–8% → expect 0.8–1.2% reduction.
Patients with longer-duration insulin-deficient T2D may see smaller A1c effects; weight benefit is more reliable.

How GLP-1s fit alongside other T2D medications

Combination	Effect	Practical note
+ Metformin	Additive glycemic; no hypoglycemia risk	Continue metformin.
+ Insulin	Glycemic synergy; hypoglycemia risk	Reduce mealtime insulin 10–20% at start; expect continued reductions during titration.
+ Sulfonylurea	Glycemic synergy; hypoglycemia risk	Reduce sulfonylurea dose 25–50% at start; consider tapering off.
+ SGLT2 inhibitor	Additive A1c; complementary CV/renal benefits	Increasingly common combo, especially with CKD or HFpEF benefit profile.
+ DPP-4 inhibitor	Mechanistic overlap; not used together	Stop DPP-4i when starting GLP-1.
+ Thiazolidinedione	Combinable	Watch for weight regain from TZD attenuating GLP-1 benefit.

Cardiovascular benefit in T2D

Semaglutide (Ozempic) and dulaglutide (Trulicity) have FDA-approved labels for MACE reduction in T2D + established CV disease, based on SUSTAIN-6 and REWIND respectively. Tirzepatide's CV outcome trial (SURPASS-CVOT) is reading out 2026; the agency is expected to consider a CV indication based on results.

Renal benefit in T2D + CKD

The FLOW trial (NEJM 2024) showed semaglutide reduced major kidney events 24% in T2D + CKD. Stopped early for efficacy. This positions semaglutide alongside SGLT2 inhibitors as a renoprotective agent in T2D + CKD. See our CKD page for details.

What about compounded GLP-1 for T2D?

Patients with T2D considering compounded semaglutide or tirzepatide should weigh two factors: (1) most insurance plans cover Ozempic or Mounjaro at meaningful copay levels for T2D, making cash-pay compounded less attractive than for weight indication; (2) compounded medications are not FDA-approved and do not have the manufacturer-supported clinical infrastructure (patient assistance programs, dose-titration support) that branded products do for the T2D indication. Many T2D patients are better served by working with their prescriber to access branded GLP-1 through insurance. For patients without coverage or with high deductibles, compounded GLP-1 is a reasonable consideration. The clinical effect of the active ingredient is the same; everything else differs.

Provider considerations for T2D-specific care

If you have T2D and are considering a telehealth GLP-1 provider, key questions:

Will they coordinate care with your primary care physician or endocrinologist?
How will they handle hypoglycemia management if you're on insulin or a sulfonylurea?
What is their protocol for A1c monitoring and follow-up?
Do they require recent labs (A1c, BMP) before initiating therapy?

See our NexLife review for an example of how a top-rated program structures T2D-relevant care.